BioRestorative Therapies

04/02/2026

We have developed a new class of high-performance cosmetic and dermatological products developed in a cGMP ISO-7 certified facility. Our BioCosmeceuticals line blends cutting-edge biologic innovation with clinical-grade quality to redefine aesthetic care.

Learn more here: bit.ly/4sN69Rj

U.S. Food and Drug Administration

03/30/2026

announced blinded data from its Phase 2 evaluating hypoxic-cultured mesenchymal for the treatment of chronic lumbar disc disease at the 2026 Orthopaedic Research Society Annual Meeting this weekend.

The data showed 50% or more of patients reporting >50% improvement in key pain and function scales with no adverse events related to dose-limiting toxicities associated with hypoxic-cultured mesenchymal stem cells.

Full press release here: bit.ly/4sGF3LP

03/27/2026

.

announces new, blinded data on ~45 patients from its Phase 2 evaluating hypoxic-cultured mesenchymal for the treatment of chronic lumbar disc disease.

These data have been accepted for presentation at the 2026 Orthopaedic Research Society Annual Meeting, which will be held March 27-31, 2026, at the Charlotte Convention Center in Charlotte, North Carolina.

Full press release here: https://ir.biorestorative.com/news-events/press-releases/detail/238/biorestorative-therapies-to-present-positive-phase-2-blinded-data-for-brtx-100-demonstrating-meaningful-improvements-in-pain-and-function-in-chronic-lumbar-disc-disease

03/26/2026

CEO Lance Alstodt joined Will Tjernlund on the to discuss our innovative stem cell therapies targeting chronic pain and metabolic disorders.

The discussion explores our therapeutic products, clinical trials, market potential, and future plans, providing insights into regenerative medicine and biotech investment strategies.

Tune in today!

Spotify: https://open.spotify.com/episode/1pYPO0YkymhXaxpTIv6HMM

Apple Podcasts: https://podcasts.apple.com/us/podcast/biorestorative-therapies-%24brtx-ep-059-nano-cap-podcast/id1725050280?i=1000756829667

03/24/2026

Over 25 million Americans live with chronic lower back pain each year and traditional treatments aren’t cutting it.

BRTX-100 is exploring a different approach: a single-injection therapy using a patient’s own stem cells to target and help repair damaged spinal discs.

Learn more about our Phase 2 progress: biorestorative.com/brtx-100-2

03/19/2026

announces new, blinded data on ~45 patients from its Phase 2 evaluating hypoxic-cultured mesenchymal for the treatment of chronic lumbar disc disease.

These data have been accepted for presentation at the 2026 Orthopaedic Research Society Annual Meeting, which will be held March 27-31, 2026, at the Charlotte Convention Center in Charlotte, North Carolina.

Full press release here: https://ir.biorestorative.com/news-events/press-releases/detail/238/biorestorative-therapies-to-present-positive-phase-2-blinded-data-for-brtx-100-demonstrating-meaningful-improvements-in-pain-and-function-in-chronic-lumbar-disc-disease

03/17/2026

, read the latest letter to shareholders from CEO, Lance Alstodt. He details the primary focus and goals for 2026 including advancing BRTX-100 into late-stage development with regulatory clarity and operational readiness for BLA approval.

Read what plans to achieve in terms of clinical programs, regulatory strategy, commercial initiatives, and capital positioning.

Learn more: https://ir.biorestorative.com/news-events/press-releases/detail/236/biorestorative-therapies-inc-issues-letter-to-shareholders-highlighting-major-milestones-regulatory-alignment-clinical-execution-and-capital-strategy

U.S. Food and Drug Administration

03/11/2026

The commercial leadership team had a great time participating in IBS & Be+Well Beauty and Wellness Shows' latest event at the Javits Center in New York City.

Check out a few snapshots of our team at one of the largest professional beauty, spa, and wellness trade events in the U.S., including our scientifically validated exosomes being delivered below the skin surface using JetPeel by TavTech technology!

NYLO Aesthetics

03/10/2026

Each year, over 25 million Americans suffer from chronic lower back pain and yet, traditional treatments are failing. BRTX-100 may offer a new path forward. Our single-injection therapy uses the patient’s own scientifically enhanced stem cells to directly target and begin repairing the damaged disc.

Learn more about phase 2 here: biorestorative.com/brtx-100-2

U.S. Food and Drug Administration

06/18/2025

https://www.globenewswire.com/news-release/2025/06/18/3101583/0/en/BioRestorative-to-Participate-in-Benzinga-All-Access-Show-Today-to-Discuss-Compelling-BRTX-100-Clinical-Data-Leadership-Enhancements-and-Strategic-updates.html

MELVILLE, N.Y., June 18, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical...

06/17/2025

https://www.globenewswire.com/news-release/2025/06/17/3100770/0/en/BioRestorative-Announces-Share-Repurchase-Program.html

MELVILLE, N.Y., June 17, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical...

06/13/2025

https://ir.biorestorative.com/news-events/press-releases/detail/218/biorestorative-reports-compelling-preliminary-data-for-fda-fast-tracked-brtx-100-an-autologous-stem-cell-therapy-to-treat-chronic-lumbar-disc-disease

– The International Society for Stem Cell Research (“ISSCR”) 2025 Annual Meeting is the world’s foremost gathering of stem cell…...